Piper Jaffray raised its rating on Codexis CDXS from Underweight to Neutral while reiterating its price target at $2 per share.
Piper Jaffray commented, "A central tenet in our previous (Underweight) rating on shares of CDXS was a structural shift in the company's relationship with Shell – an event that came to fruition with the announcement yesterday that the two parties are now non-exclusive and that Shell's R&D payments will cease. As a result, we have elected to upgrade shares to Neutral, while maintaining our $2 price target. The new agreement stipulates a ‘low, single-digit' royalty percentage to be paid to Shell out of any future net sales of CodeXyme to thirdparties, with no apparent sunset."
Codexis closed at $2.20 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in